Vives, S.; Quintela, D.; Morgades, M.; Cano-Ferri, I.; Serrano, A.; Acuña-Cruz, E.; Cervera, M.; Díaz-Beyá, M.; Vidriales, B.; Raposo-Puglia, J.Á.;
et al. Salvage Therapy with Second-Generation Inhibitors for FLT3 Mutated Acute Myeloid Leukemia: A Real-World Study by the CETLAM and PETHEMA Groups. Cancers 2024, 16, 4028.
https://doi.org/10.3390/cancers16234028
AMA Style
Vives S, Quintela D, Morgades M, Cano-Ferri I, Serrano A, Acuña-Cruz E, Cervera M, Díaz-Beyá M, Vidriales B, Raposo-Puglia JÁ,
et al. Salvage Therapy with Second-Generation Inhibitors for FLT3 Mutated Acute Myeloid Leukemia: A Real-World Study by the CETLAM and PETHEMA Groups. Cancers. 2024; 16(23):4028.
https://doi.org/10.3390/cancers16234028
Chicago/Turabian Style
Vives, Susana, David Quintela, Mireia Morgades, Isabel Cano-Ferri, Alfons Serrano, Evelyn Acuña-Cruz, Marta Cervera, Marina Díaz-Beyá, Belén Vidriales, José Ángel Raposo-Puglia,
and et al. 2024. "Salvage Therapy with Second-Generation Inhibitors for FLT3 Mutated Acute Myeloid Leukemia: A Real-World Study by the CETLAM and PETHEMA Groups" Cancers 16, no. 23: 4028.
https://doi.org/10.3390/cancers16234028
APA Style
Vives, S., Quintela, D., Morgades, M., Cano-Ferri, I., Serrano, A., Acuña-Cruz, E., Cervera, M., Díaz-Beyá, M., Vidriales, B., Raposo-Puglia, J. Á., Arnan, M., Garrido, A., Balerdi, A., Cabello, A. I., Herrera-Puente, P., Serrano, J., Coll, R., Tormo, M., López-Marín, J.,
... Montesinos, P., on behalf of the CETLAM and PETHEMA Groups.
(2024). Salvage Therapy with Second-Generation Inhibitors for FLT3 Mutated Acute Myeloid Leukemia: A Real-World Study by the CETLAM and PETHEMA Groups. Cancers, 16(23), 4028.
https://doi.org/10.3390/cancers16234028
